Core Viewpoint - Jiyuan Holdings Group Co., Ltd. has been announced to be delisted from the Shenzhen Stock Exchange due to its stock price falling below 1 yuan for twenty consecutive trading days, with the delisting effective on May 29, 2025 [1] Group 1: Company Performance and Financials - Jiyuan Holdings, originally a chemical company, transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical, establishing a dual business model of "chemicals + pharmaceuticals" [3] - The company engaged in aggressive acquisitions, acquiring over ten companies within three years, with its pharmaceutical segment accounting for 70% of total revenue at its peak, leading to a market capitalization exceeding 5 billion yuan [3] - However, the acquired companies' performance deteriorated post-acquisition, with Zhejiang Yalida Gelatin Co., Ltd. reporting a 94% drop in net profit in 2019, and Changchun Puhua Pharmaceutical Co., Ltd. incurring direct losses [3] - Since 2019, Jiyuan Holdings has been in a continuous loss state, accumulating losses exceeding 3.7 billion yuan [4] Group 2: Attempts at Restructuring and Ownership Changes - The company has made several attempts to change ownership in response to its financial struggles, but all efforts have failed [5] - In 2019, an agreement to transfer shares to Jilin Jisheng Asset Management was terminated due to disagreements on key terms [5] - A proposed acquisition of Xiu Zheng Pharmaceutical was also abandoned due to regulatory uncertainties, leading to scrutiny from the Shenzhen Stock Exchange [5][6] - In 2020, a deal to transfer control to Ben Cao Hui Pharmaceutical faced disputes over payment, resulting in legal proceedings [6]

Core Viewpoint - *ST Jiyuan's stock has been decided to be delisted by the Shenzhen Stock Exchange due to its closing price being below 1 yuan for twenty consecutive trading days, effective May 29, 2025 [2] Group 1: Company Overview - *ST Jiyuan primarily operates in the pharmaceutical and health industry, encompassing pharmaceutical manufacturing, retail, research and development, medical care, and investment [2] - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in August 2010 [2] Group 2: Delisting Details - The decision for delisting was made on May 26, 2025, and the company is required to ensure its shares can enter the National Small and Medium Enterprises Share Transfer System within 45 trading days after delisting [2] - The company will not enter a delisting transition period [2] Group 3: Future Actions - *ST Jiyuan has appointed Shanxi Securities Co., Ltd. as its main broker to assist with share transfer services and related matters following the delisting [3] - An agreement for share transfer services was signed on May 27, 2025, to handle the necessary procedures for the delisting [3]

Group 1 - The company, Jiyuan Holdings Group Co., Ltd., has announced the convening of its third extraordinary general meeting of shareholders for 2025, scheduled for April 16, 2025 [1][2] - The meeting will include both on-site and online voting options for shareholders, with specific time slots designated for each [2][4] - Shareholders must register for the meeting, providing necessary documentation depending on their status as individual or corporate shareholders [5][6] Group 2 - The meeting will review specific proposals, with details available in a prior announcement made on March 31, 2025 [4] - The company has outlined the procedures for online voting, including the requirement for shareholders to authenticate their identity before participating [6][9] - An authorization letter template is provided for shareholders who wish to delegate their voting rights to another individual [8][9]

证券代码：300108 证券简称：*ST 吉药 公告编号：2025-023 吉药控股集团股份有限公司 关于股票交易异常波动公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 1、吉药控股集团股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日 披露了《2024 年度业绩预告》（公告编号：2025-007），预计 2024 年度期末净 资产为-83,000 万元— -118,000 万元（未经审计）。如果公司 2024 年度期末经 审计净资产为负值，根据《深圳证券交易所创业板股票上市规则》第 10.3.11 条 的规定，公司股票将被终止上市。敬请广大投资者审慎理性决策，注意投资风 险。 2、公司 2024 年度审计报告的意见类型尚存在不确定性，具体以 2024 年 审计报告为准。如果公司 2024 年度财务会计报告被出具保留意见、无法表示意 见或者否定意见的审计报告，根据《创业板股票上市规则》第 10.3.11 条的规定， 公司股票将被终止上市。上市公司出现两项以上终止上市情形的，股票按照先 触及先适用的原则实施终止上市。敬请广大投 ...

证券代码：300108 证券简称：*ST吉药 公告编号：2025-019 吉药控股集团股份有限公司 关于公司控股股东及其一致行动人股份将被 司法拍卖的进展公告 | 2 | 卢忠奎 | 6,000,000 | - | 淘宝网 | - | - | 流拍 | | --- | --- | --- | --- | --- | --- | --- | --- | | 3 | 黄克凤 | 6,000,000 | - | 淘宝网 | - | - | 流拍 | | 4 | 卢忠奎及黄克凤 | 4,413,104 | - | 淘宝网 | - | - | 流拍 | | | 合计 | 22,413,104 | | | | | | 二、股东股份累计被司法冻结或拍卖情况 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次司法拍卖的标的物为吉药控股集团股份有限公司（以下简称"公司"） 控股股东、实际控制人卢忠奎先生所持有的公司无限售条件流通股 14,808,104 股（占其持有公司股份数量的比例为 98.74%，占公司股份总数的比例为 2.22%） 及其一致行动人黄克凤 ...

证券代码：300108 证券简称：*ST 吉药 公告编号：2025-021 吉药控股集团股份有限公司 关于公司股票存在可能因股价低于面值 被终止上市的风险提示公告 1、2025 年 2 月 24 日，吉药控股集团股份有限公司（以下简称"公司"） 股票收盘价格为 0.98元/股，根据《深圳证券交易所创业板股票上市规则》第 10.2.3 条的规定，上市公司首次出现股票收盘价格低于 1 元情形的，应当在次一交易 日披露公司股票可能被终止上市的风险提示公告。敬请广大投资者理性投资， 注意风险。 2、根据《深圳证券交易所创业板股票上市规则》第 10.2.1 条的规定，若公 司出现连续二十个交易日的股票收盘价均低于 1 元，公司股票将被终止上市。 敬请广大投资者注意投资风险。 3、公司于 2024 年 4 月 29 日披露了《关于公司股票交易被实行退市风险警 示暨停牌的公告》（公告编号：2024-034），公司股票自 2024 年 4 月 30 日被实 施退市风险警示，若公司出现《深圳证券交易所创业板股票上市规则》第 10.3.11 条规定的任一情形，公司股票将被终止上市。具体内容详见公司同日披露的《关 于公司股票可能被 ...

证券代码：300108 证券简称：*ST 吉药 公告编号：2025-020 吉药控股集团股份有限公司 关于公司股票可能被终止上市的第三次风险提示公告 本公司及其董事会全体成员保证公告内容真实、准确、完整，公告不存 在虚假记载、误导性陈述或重大遗漏。 特别提示： 1、吉药控股集团股份有限公司（以下简称"公司"）于 2024 年 4 月 29 日 披露了《关于公司股票交易被实行退市风险警示暨停牌的公告》（公告编号： 2024-034），公司股票自 2024 年 4 月 30 日被实施退市风险警示，若公司出现《深 圳证券交易所创业板股票上市规则》第 10.3.11 条规定的任一情形，公司股票将 被终止上市。敬请广大投资者注意投资风险。 2、根据《深圳证券交易所创业板股票上市规则》第 10.3.5 条第一款规定： "上市公司因触及第 10.3.1 条第一款第一项至第三项情形，其股票交易被实施 退市风险警示后，应当在其股票被实施退市风险警示当年的会计年度结束后一 个月内，披露股票可能被终止上市的风险提示公告，在首次风险提示公告披露 后至年度报告披露前，每十个交易日披露一次风险提示公告。"根据该规定， 公司应当披露股票可 ...